Literature DB >> 30674229

More accurate cancer-related excess mortality through correcting background mortality for extra variables.

C Touraine1,2, N Grafféo3,4, R Giorgi2,5.   

Abstract

Relative survival methods used to estimate the excess mortality of cancer patients rely on the background (or expected) mortality derived from general population life tables. These methods are based on splitting the observed mortality into the excess mortality and the background mortality. By assuming a regression model for the excess mortality, usually a Cox-type model, one may investigate the effects of certain covariates on the excess mortality. Some covariates are cancer-specific whereas others are variables that may influence the background mortality as well. The latter should be taken into account in the background mortality to avoid biases in estimating their effects on the excess mortality. Unfortunately, the available life table might not include such variables and, consequently, might provide inaccurate values of the background mortality. We propose a model that uses multiplicative parameters to correct potentially inaccurate background mortality. The model can be seen as an extension of the frequently used Estève model because we assume a Cox-type model for the excess mortality with a piecewise constant baseline function and introduce additional parameters that multiply the background mortality. The original and the extended model are compared, first in a simulation study, then in an application to colon cancer registry data.

Entities:  

Keywords:  Excess hazard; cancer; life tables; net survival; relative survival

Mesh:

Year:  2019        PMID: 30674229     DOI: 10.1177/0962280218823234

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  1 in total

1.  Correcting inaccurate background mortality in excess hazard models through breakpoints.

Authors:  Robert Darlin Mba; Juste Aristide Goungounga; Nathalie Grafféo; Roch Giorgi
Journal:  BMC Med Res Methodol       Date:  2020-10-29       Impact factor: 4.615

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.